Induction of apoptosis and role of paclitaxel-loaded hyaluronic acid-crosslinked nanoparticles in the regulation of AKT and RhoA.
AKT
Rho A
apoptosis
drug delivery
flow cytometry
hyaluronan
paclitaxel
Journal
Journal of advanced pharmaceutical technology & research
ISSN: 2231-4040
Titre abrégé: J Adv Pharm Technol Res
Pays: India
ID NLM: 101537797
Informations de publication
Date de publication:
Historique:
received:
28
02
2020
revised:
11
04
2020
accepted:
22
04
2020
entrez:
26
10
2020
pubmed:
27
10
2020
medline:
27
10
2020
Statut:
ppublish
Résumé
Cancer is a complex multifactorial disease and leading causes of death worldwide. Despite the development of many anticancer drugs, there is a reduced survival rate due to severe side effects. The nontargeted approach of convention drugs is one of the leading players in context to toxicity. Hyaluronan is a versatile bio-polymer and ligand of the receptor (CD44) on cancer cells. The MCF-7 and HT-29 cancer cell lines treated with hyaluronic acid-paclitaxel (HA-PTX) showed the distinguishing morphological features of apoptosis. Flow cytometric analysis showed that HA-PTX induces apoptosis as a significant mode of cell death. The activation level of tumor suppressor protein (p53) increased after PTX treatment in MCF-7, but no changes observed in HT-29 might be due to hereditary mutations. The lack of suppression in AKT and Rho A protein suggest the use of possible inhibitors in future studies which might could play a role in increasing the sensitivity of drug towards mutated cells line and reducing the possibilities for cancer cell survival, migration, and metastasis.
Identifiants
pubmed: 33102192
doi: 10.4103/japtr.JAPTR_26_20
pii: JAPTR-11-101
pmc: PMC7574732
doi:
Types de publication
Journal Article
Langues
eng
Pagination
101-106Informations de copyright
Copyright: © 2020 Journal of Advanced Pharmaceutical Technology & Research.
Déclaration de conflit d'intérêts
There are no conflicts of interest.
Références
J Biol Chem. 1996 Aug 23;271(34):20246-9
pubmed: 8702756
Cancer Lett. 2006 Jun 8;237(1):56-66
pubmed: 16009487
Trends Cell Biol. 2008 May;18(5):210-9
pubmed: 18394899
J Biol Chem. 2004 Apr 9;279(15):15196-203
pubmed: 14722122
Cancer Cell. 2003 Oct;4(4):257-62
pubmed: 14585353
Lancet. 1997 May 24;349(9064):1556
pubmed: 9167490
Nat Rev Cancer. 2018 Feb;18(2):89-102
pubmed: 29242642
Oncogene. 2006 Aug 7;25(34):4633-46
pubmed: 16892078
World J Microbiol Biotechnol. 2018 Jul 14;34(8):118
pubmed: 30008019
Nanomaterials (Basel). 2018 Feb 03;8(2):
pubmed: 29401694
Cancer Chemother Pharmacol. 1999;44(3):217-27
pubmed: 10453723
Adv Pharm Bull. 2019 Jun;9(2):205-218
pubmed: 31380246
Biochim Biophys Acta. 2014 Dec;1846(2):342-52
pubmed: 25109892
Drug Resist Updat. 2002 Dec;5(6):234-48
pubmed: 12531180
CA Cancer J Clin. 2012 Jan-Feb;62(1):10-29
pubmed: 22237781
Oncogene. 2001 Jun 28;20(29):3806-13
pubmed: 11439344
Res Pharm Sci. 2019 Jun;14(3):273-285
pubmed: 31160905
Cell Commun Signal. 2010 Sep 07;8:23
pubmed: 20822528
Cancer Res. 2018 Jun 15;78(12):3321-3336
pubmed: 29669760
Apoptosis. 2004 Nov;9(6):667-76
pubmed: 15505410
Cell Death Differ. 2002 Jun;9(6):636-42
pubmed: 12032672
Adv Cancer Res. 2014;123:255-75
pubmed: 25081533
Cancer Res. 1997 Mar 1;57(5):870-4
pubmed: 9041188
Proc Natl Acad Sci U S A. 1990 Oct;87(19):7555-9
pubmed: 1699228
Asian Pac J Cancer Prev. 2019 Dec 01;20(12):3555-3562
pubmed: 31870094
J Cell Physiol. 2003 Oct;197(1):8-29
pubmed: 12942537
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Cancer Res. 2004 Apr 15;64(8):2782-92
pubmed: 15087394
Curr Cancer Drug Targets. 2006 Feb;6(1):1-14
pubmed: 16475973